KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cash from Investing Activities: 2019-2024

Historic Cash from Investing Activities for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to $260.1 million.

  • Recursion Pharmaceuticals' Cash from Investing Activities rose 44.13% to -$2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $259.8 million, marking a year-over-year increase of 1552.78%. This contributed to the annual value of $260.1 million for FY2024, which is 2642.62% up from last year.
  • Recursion Pharmaceuticals' Cash from Investing Activities amounted to $260.1 million in FY2024, which was up 2,642.62% from -$10.2 million recorded in FY2023.
  • Recursion Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $260.1 million during FY2024, with a 5-year trough of -$271.7 million in FY2021.
  • Over the past 3 years, Recursion Pharmaceuticals' median Cash from Investing Activities value was $193.2 million (recorded in 2022), while the average stood at $147.7 million.
  • In the last 5 years, Recursion Pharmaceuticals' Cash from Investing Activities slumped by 3,009.20% in 2021 and then skyrocketed by 2,642.62% in 2024.
  • Recursion Pharmaceuticals' Cash from Investing Activities (Yearly) stood at -$8.7 million in 2020, then crashed by 3,009.20% to -$271.7 million in 2021, then soared by 171.11% to $193.2 million in 2022, then slumped by 105.29% to -$10.2 million in 2023, then spiked by 2,642.62% to $260.1 million in 2024.